SCHEMBL16214947

SCHEMBL16214947

[N-]=[N+]=N[C@]1(COC(=O)c2ccccc2)O[C@@H](n2ccc(=O)[nH]c2=O)[C@@H](F)[C@@H]1OC(=O)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37
KMT2A Q03164 1/20 0.37
P2RY2 P41231 8/20 0.34
P2RY6 Q15077 4/20 0.34
P2RY4 P51582 1/20 0.34
P2RY12 Q9H244 5/20 0.33
NT5E P21589 1/20 0.33
P2RY14 Q15391 1/20 0.33
SLC28A1 O00337 1/20 0.32
SLC28A2 O43868 1/20 0.32
SLC29A1 Q99808 1/20 0.32
SLC28A3 Q9HAS3 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16214981 1.00 POLB (0.37) POLBHSD17B10MEN1USP2KMT2A
SCHEMBL15375889 0.93 P2RY2 (0.35) POLBHSD17B10MEN1USP2KMT2A
SCHEMBL16214983 0.92 POLB (0.35) POLBHSD17B10MEN1USP2KMT2A
SCHEMBL15386764 0.92 POLB (0.35) POLBHSD17B10MEN1USP2KMT2A
SCHEMBL15385711 0.92 POLB (0.35) POLBHSD17B10MEN1USP2KMT2A
SCHEMBL13592886 0.91 POLB (0.41) POLBHSD17B10MEN1USP2KMT2A
SCHEMBL15281799 0.91 POLB (0.41) POLBHSD17B10MEN1USP2KMT2A
SCHEMBL16214991 0.90 POLB (0.37) POLBHSD17B10MEN1USP2KMT2A
SCHEMBL16305898 0.88 POLB (0.40) POLBHSD17B10MEN1USP2KMT2A
SCHEMBL15075014 0.88 POLB (0.40) POLBHSD17B10MEN1USP2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264610-A1 AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS ALIOS BIOPHARMA INC (US) 2016-09-15 US disclosed
US-9346848-B2 Azido nucleosides and nucleotide analogs ALIOS BIOPHARMA, INC. (US) 2016-05-24 US disclosed
US-20150183819-A1 AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. 2015-07-02 US disclosed
US-8877731-B2 Azido nucleosides and nucleotide analogs ALIOS BIOPHARMA, INC. (US) 2014-11-04 US disclosed
WO-2012040124-A1 AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-29 WO disclosed
US-20120070415-A1 AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264610-A1 AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS PNP, ADA, ADAR POLB 954/4885HSD17B10 4799/4885MEN1 3666/4885
US-20120070415-A1 AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS PNP, ADA, ADAR POLB 954/4885HSD17B10 4799/4885MEN1 3666/4885
US-20150183819-A1 AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS PNP, ADA, ADAR POLB 954/4885HSD17B10 4799/4885MEN1 3666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.